- Home
- MRSN vs MDIA Comparison
MRSN vs MDIA Comparison
Compare MRSN & MDIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- MDIA
- Stock Information
- Founded
- MRSN 2001
- MDIA 2019
- Country
- MRSN United States
- MDIA United States
- Employees
- MRSN N/A
- MDIA N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- MDIA Broadcasting
- Sector
- MRSN Health Care
- MDIA Consumer Discretionary
- Exchange
- MRSN Nasdaq
- MDIA Nasdaq
- Market Cap
- MRSN 71.9M
- MDIA 55.6M
- IPO Year
- MRSN 2017
- MDIA N/A
- Fundamental
- Price
- MRSN $0.48
- MDIA $1.09
- Analyst Decision
- MRSN Buy
- MDIA
- Analyst Count
- MRSN 4
- MDIA 0
- Target Price
- MRSN $4.33
- MDIA N/A
- AVG Volume (30 Days)
- MRSN 3.8M
- MDIA 16.4K
- Earning Date
- MRSN 03-03-2025
- MDIA 03-31-2025
- Dividend Yield
- MRSN N/A
- MDIA N/A
- EPS Growth
- MRSN N/A
- MDIA N/A
- EPS
- MRSN N/A
- MDIA N/A
- Revenue
- MRSN $40,497,000.00
- MDIA $69,296,000.00
- Revenue This Year
- MRSN N/A
- MDIA N/A
- Revenue Next Year
- MRSN $67.68
- MDIA N/A
- P/E Ratio
- MRSN N/A
- MDIA N/A
- Revenue Growth
- MRSN 9.88
- MDIA 94.96
- 52 Week Low
- MRSN $0.45
- MDIA $0.40
- 52 Week High
- MRSN $5.96
- MDIA $6.86
- Technical
- Relative Strength Index (RSI)
- MRSN 35.88
- MDIA 44.65
- Support Level
- MRSN $0.49
- MDIA $1.00
- Resistance Level
- MRSN $0.56
- MDIA $1.23
- Average True Range (ATR)
- MRSN 0.05
- MDIA 0.08
- MACD
- MRSN 0.02
- MDIA -0.00
- Stochastic Oscillator
- MRSN 28.11
- MDIA 38.46
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.